Total Funding
1
Total FundingSeries B raised
Growth Score
pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3031490
Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases.
Acquired by 
Alexion Pharmaceuticals
- Woodruff Emlen: President and co-founder
About the Company
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors
in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
